The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice - PubMed (original) (raw)
doi: 10.1038/nm0901-1052.
M T Wilson, I Serizawa, L Wu, N Singh, O V Naidenko, T Miura, T Haba, D C Scherer, J Wei, M Kronenberg, Y Koezuka, L Van Kaer
Affiliations
- PMID: 11533710
- DOI: 10.1038/nm0901-1052
The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice
S Hong et al. Nat Med. 2001 Sep.
Abstract
Diabetes in non-obese diabetic (NOD) mice is mediated by pathogenic T-helper type 1 (Th1) cells that arise because of a deficiency in regulatory or suppressor T cells. V alpha 14-J alpha 15 natural killer T (NKT) cells recognize lipid antigens presented by the major histocompatibility complex class I-like protein CD1d (refs. 3,4). We have previously shown that in vivo activation of V alpha 14 NKT cells by alpha-galactosylceramide (alpha-GalCer) and CD1d potentiates Th2-mediated adaptive immune responses. Here we show that alpha-GalCer prevents development of diabetes in wild-type but not CD1d-deficient NOD mice. Disease prevention correlated with the ability of alpha-GalCer to suppress interferon-gamma but not interleukin-4 production by NKT cells, to increase serum immunoglobulin E levels, and to promote the generation of islet autoantigen-specific Th2 cells. Because alpha-GalCer recognition by NKT cells is conserved among mice and humans, these findings indicate that alpha-GalCer might be useful for therapeutic intervention in human diseases characterized by Th1-mediated pathology such as Type 1 diabetes.
Similar articles
- Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A. Sharif S, et al. Nat Med. 2001 Sep;7(9):1057-62. doi: 10.1038/nm0901-1057. Nat Med. 2001. PMID: 11533711 - Synthetic glycolipid OCH prevents insulitis and diabetes in NOD mice.
Mizuno M, Masumura M, Tomi C, Chiba A, Oki S, Yamamura T, Miyake S. Mizuno M, et al. J Autoimmun. 2004 Dec;23(4):293-300. doi: 10.1016/j.jaut.2004.09.008. J Autoimmun. 2004. PMID: 15571923 - Prevention of injury-induced suppression of T-cell immunity by the CD1d/NKT cell-specific ligand alpha-galactosylceramide.
Tulley JM, Palmer JL, Gamelli RL, Faunce DE. Tulley JM, et al. Shock. 2008 Feb;29(2):269-77. doi: 10.1097/shk.0b013e31811ff60c. Shock. 2008. PMID: 17693934 - CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against Type 1 diabetes.
Mi QS, Meagher C, Delovitch TL. Mi QS, et al. Novartis Found Symp. 2003;252:146-60; discussion 160-4, 203-10. Novartis Found Symp. 2003. PMID: 14609217 Review. - The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice.
Cardell SL. Cardell SL. Clin Exp Immunol. 2006 Feb;143(2):194-202. doi: 10.1111/j.1365-2249.2005.02942.x. Clin Exp Immunol. 2006. PMID: 16412042 Free PMC article. Review.
Cited by
- Probiotic treatment with viable α-galactosylceramide-producing Bacteroides fragilis reduces diabetes incidence in female nonobese diabetic mice.
Hansen CHF, Jozipovic D, Zachariassen LF, Nielsen DS, Hansen AK, Buschard K. Hansen CHF, et al. J Diabetes. 2024 Aug;16(8):e13593. doi: 10.1111/1753-0407.13593. J Diabetes. 2024. PMID: 39136533 Free PMC article. - Human CD4+ iNKT cell adoptive immunotherapy induces anti-tumour responses against CD1d-negative EBV-driven B lymphoma.
Baiu DC, Sharma A, Schehr JL, Basu J, Smith KA, Ohashi M, Johannsen EC, Kenney SC, Gumperz JE. Baiu DC, et al. Immunology. 2024 Aug;172(4):627-640. doi: 10.1111/imm.13799. Epub 2024 May 13. Immunology. 2024. PMID: 38736328 - Berberine: A natural modulator of immune cells in multiple sclerosis.
Yazdanpanah E, Dadfar S, Shadab A, Orooji N, Nemati M, Pazoki A, Esmaeili SA, Baharlou R, Haghmorad D. Yazdanpanah E, et al. Immun Inflamm Dis. 2024 Mar;12(3):e1213. doi: 10.1002/iid3.1213. Immun Inflamm Dis. 2024. PMID: 38477663 Free PMC article. Review. - The immune system in neurological diseases: What innate-like T cells have to say.
Wyatt-Johnson SK, Afify R, Brutkiewicz RR. Wyatt-Johnson SK, et al. J Allergy Clin Immunol. 2024 Apr;153(4):913-923. doi: 10.1016/j.jaci.2024.02.003. Epub 2024 Feb 15. J Allergy Clin Immunol. 2024. PMID: 38365015 Review. - Harnessing invariant natural killer T cells to control pathological inflammation.
Bharadwaj NS, Gumperz JE. Bharadwaj NS, et al. Front Immunol. 2022 Sep 15;13:998378. doi: 10.3389/fimmu.2022.998378. eCollection 2022. Front Immunol. 2022. PMID: 36189224 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical